MIM
CLDX icon

MetLife Investment Management’s Celldex Therapeutics CLDX Stock Holding History

MetLife Investment Management’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.69M Buy
45,527
+8,864
+24% +$286K 0.01% 1248
2026
Q1 		$1.16M Sell
36,663
-349
-0.9% -$9.51K 0.01% 1330
2025
Q4 		$1.01M Sell
37,012
-1,992
-5% -$52.5K ﹤0.01% 1429
2025
Q3 		$1.01M Hold
39,004
– – ﹤0.01% 1441
2025
Q2 		$794K Hold
39,004
– – ﹤0.01% 1439
2025
Q1 		$708K Sell
39,004
-616
-2% -$13.8K ﹤0.01% 1532
2024
Q4 		$1M Buy
39,620
+2,288
+6% +$62.2K 0.01% 1413
2024
Q3 		$1.27M Hold
37,332
– – 0.01% 1257
2024
Q2 		$1.38M Buy
37,332
+5,568
+18% +$210K 0.01% 1169
2024
Q1 		$1.33M Buy
31,764
+7,691
+32% +$316K 0.01% 1142
2023
Q4 		$955K Hold
24,073
– – 0.01% 1319
2023
Q3 		$662K Hold
24,073
– – 0.01% 1463
2023
Q2 		$817K Buy
24,073
+349
+1% +$11.8K 0.01% 1382
2023
Q1 		$854K Sell
23,724
-901
-4% -$38.9K 0.01% 1310
2022
Q4 		$1.1M Sell
24,625
-583
-2% -$20.8K 0.01% 1178
2022
Q3 		$709K Hold
25,208
– – 0.01% 1388
2022
Q2 		$680K Hold
25,208
– – 0.01% 1449
2022
Q1 		$859K Buy
25,208
+9,152
+57% +$293K 0.01% 1430
2021
Q4 		$620K Hold
16,056
– – 0.01% 1394
2021
Q3 		$867K Buy
16,056
+1,549
+11% +$72.7K 0.01% 1194
2021
Q2 		$485K Buy
+14,507
New +$398K ﹤0.01% 1592
2018
Q2 		– Sell
-1,561
Closed -$55K – 2175
2018
Q1 		$55K Sell
1,561
-2,822
-64% -$109K ﹤0.01% 2169
2017
Q4 		$187K Buy
+4,383
New +$188K ﹤0.01% 1960

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

MetLife Investment Management's CLDX Position: Q2 2026 in Review

MetLife Investment Management increased its Celldex Therapeutics (CLDX) stake by 24% in Q2 2026, buying an estimated $286K and bringing the position to 45,527 shares worth $1.69M. The position accounts for 0.01% of the portfolio, ranked #1248.

MetLife Investment Management first reported a position in CLDX in Q4 2017 and has held it in 23 quarters since. 253 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

  • MetLife Investment Management held 45,527 shares of Celldex Therapeutics worth $1.69M as of Q2 2026.
  • MetLife Investment Management bought 8,864 Celldex Therapeutics shares in Q2 2026, an estimated $286K.
  • Celldex Therapeutics made up 0.01% of MetLife Investment Management's portfolio in Q2 2026, its #1248 holding.
  • MetLife Investment Management first reported a position in Celldex Therapeutics in Q4 2017 and has held it in 23 quarters since.
  • 253 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.